Illumina Accelerator

The AI engine Fit Assessment

Beta

Illumina specializes in advanced technologies for analyzing genetic material, focusing on DNA, RNA, and protein analysis to support disease research and drug development. Their solutions aim to facilitate personalized medicine through innovative and scalable approaches.

Blurb

Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.

HQ Location

San Diego (United States)

Founded

1998

Employees

5001 - 10000

Total funding raised

$1.28B

Last Funding Event

Post-IPO Debt, $500.00M, September 6, 2024

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Biomarker Identification
  • Genomic Data Analysis

Illumina is an innovative technology and revolutionary assay aiming to analyze genetic variation and function. These studies help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, it strives to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.